Vaccine最新文献

{"title":"A comprehensive analysis of the current strategy for developing live attenuated vaccines against African swine fever: A systematic review and meta-analysis","authors":"Eurade Ntakiyisumba,&nbsp;Maryum Tanveer,&nbsp;Gayeon Won","doi":"10.1016/j.vaccine.2025.127243","DOIUrl":"10.1016/j.vaccine.2025.127243","url":null,"abstract":"<div><div>A systematic review and meta-analysis were conducted to evaluate the safety and effectiveness of live attenuated vaccines (LAVs) against African swine fever (ASF) in domestic pigs, focusing on three major disease outcomes: mortality, fever, and clinical signs. The findings indicated that vaccinated pigs exhibited significantly lower risks of mortality (RR = 0.30, 95 % CI: 0.24–0.39), fever (RR = 0.46, 95 % CI: 0.38–0.56), and clinical signs (RR = 0.34, 95 % CI: 0.27–0.43), compared to unvaccinated controls, corresponding to vaccine efficacies (VE) of 70 %, 54 %, and 66 %, respectively. Although this marks significant progress toward ASF control through vaccination, the presence of significant side effects in some vaccinated pigs, such as fever (RD = 0.24, 95 % CI: 0.15–0.34) and clinical reactions (RD = 0.11, 95 % CI: 0.05–0.18) indicates that current vaccine candidates require further refinement to achieve the level of safety and protection needed for field application. Subgroup analysis revealed that homologous recombination technology is the most effective attenuation strategy, with gene deletion mutants derived from virulent strains achieving a VE of 73 % against mortality, 70 % against clinical signs, and 55 % against fever. Moreover, the efficacy and safety of LAVs are strongly influenced by the viral strain used as the vaccine backbone and the challenge strain used. A more comprehensive understanding of the antigenic, pathogenic, and immunogenic variations among ASF virus strains is crucial for the development of an effective and safe vaccine.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"57 ","pages":"Article 127243"},"PeriodicalIF":4.5,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143937700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-specific effects of routine vaccinations on child survival between 12-59 months of age in Jigawa, Nigeria: A secondary analysis of the INSPIRING Jigawa trial","authors":"Elizabeth Patrick ,&nbsp;Agnese Iuliano ,&nbsp;Damola Bakare ,&nbsp;Julius Salako ,&nbsp;Funmilayo Shittu ,&nbsp;Ayobami A. Bakare ,&nbsp;Obioma Uchendu ,&nbsp;Hamish Graham ,&nbsp;Eric D. McCollum ,&nbsp;Rochelle Ann Burgess ,&nbsp;James Beard ,&nbsp;Adegoke G. Falade ,&nbsp;Carina King ,&nbsp;Tim Colbourn ,&nbsp;on behalf of the INSPIRING Consortium","doi":"10.1016/j.vaccine.2025.127211","DOIUrl":"10.1016/j.vaccine.2025.127211","url":null,"abstract":"<div><div>Nigeria contributes a substantial number of under-5 deaths and ‘zero dose’ children (i.e. children with no routine vaccinations) to the global burden each year. Vaccines are a lifesaving intervention proven to reduce child mortality from specific diseases. Non-specific effects of vaccines may further affect all-cause child mortality.</div><div>This analysis explores the association between vaccination status and child survival for children 12–59 months of age, using data from the INSPIRING trial in Jigawa, Nigeria (registration: ISRCTN39213655). Descriptive analysis and logistic regression were used, with multivariate models adjusting for the study design and child age, sex, malnutrition, maternal education, maternal age, compound size and wealth quintile. Interaction effects for child sex were explored given evidence for non-specific effects of vaccines.</div><div>We found all groups of vaccinated children to have reduced mortality compared to unvaccinated children. Children that completed the Nigerian vaccination schedule, i.e. received the second measles vaccine dose, had the lowest odds of death, with a 70 % reduction in mortality compared to an unvaccinated child (AOR: 0.30, CI: 0.18, 0.49, <em>p</em>-value <span><math><mo>&lt;</mo></math></span>0.001). A child that had basic antigens and the 1st measles dose had 30 % lower odds of death than an unvaccinated child (AOR: 0.70, CI: 0.49, 0.98, p-value <span><math><mn>0.038</mn></math></span>).</div><div>This study supports evidence that vaccines have non-specific effects on all-cause child mortality. Unvaccinated children had the highest odds of death between 12 and 59 months of age and must be reached through vaccination to improve their chances of survival. In this setting, receiving a second measles vaccine was associated with a large reduction in child mortality, and may be an effective focus for outreach campaigns in Northern Nigeria.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"57 ","pages":"Article 127211"},"PeriodicalIF":4.5,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143937702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine” [Vaccine (2015) 33(1) 108–16]","authors":"D.M. Carter ,&nbsp;C.E. Bloom ,&nbsp;G.A. Kirchenbaum ,&nbsp;V. Tsvetnitsky ,&nbsp;I. Isakova-Sivak ,&nbsp;L. Rudenko ,&nbsp;T.M. Ross","doi":"10.1016/j.vaccine.2025.127174","DOIUrl":"10.1016/j.vaccine.2025.127174","url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"57 ","pages":"Article 127174"},"PeriodicalIF":4.5,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143937705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mpox vaccine eligibility, uptake and coverage among gay, bisexual and other men who have sex with men in Aotearoa New Zealand","authors":"Peter Saxton ,&nbsp;Brooke Maria Hollingshead ,&nbsp;Joe Rich ,&nbsp;Simran Saini ,&nbsp;Koson Tony Sriamporn ,&nbsp;Peter Hanl ,&nbsp;Janine Paynter","doi":"10.1016/j.vaccine.2025.127247","DOIUrl":"10.1016/j.vaccine.2025.127247","url":null,"abstract":"<div><div>The 2022 multi-country mpox outbreak predominantly affected gay, bisexual, and other men who have sex with men (GBM). As a small country distant from transmission hotspots but vulnerable to imported cases, New Zealand's (NZ) response involved numerous challenges, including low vaccine supplies and lack of regulatory approval, prohibiting vaccine promotion and inhibiting vaccine delivery. We triangulated data sources to estimate mpox vaccine eligibility among GBM. National Immunisation Register data was used to estimate mpox vaccine coverage. Finally, we estimated the probability of a resurgent NZ epidemic using modelling by the US CDC. By April 2024, 3050 individuals had received one mpox vaccine dose and 1065 two doses. National first and second dose coverage among GBM in April 2024 was 12.6 % (range 9.1 %–16.7 %) and 4.4 % (range 2.9 %–5.8 %) respectively. Modelling predicted a &gt; 50 % chance of a future outbreak. With ongoing mpox transmission globally, vaccine coverage among GBM in NZ must urgently increase.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"57 ","pages":"Article 127247"},"PeriodicalIF":4.5,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143937698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing measles immunity among healthcare workers, a systematic review of peer-reviewed literature (2013−2023). Where do we go from here?","authors":"Yuen Fung Ng (Dave) ,&nbsp;Karen Lockhart ,&nbsp;Meena Dawar ,&nbsp;David Vigor ,&nbsp;Annalee Yassi","doi":"10.1016/j.vaccine.2025.127214","DOIUrl":"10.1016/j.vaccine.2025.127214","url":null,"abstract":"<div><h3>Background</h3><div>Measles, a highly contagious disease, is experiencing a global resurgence, posing significant risks to healthcare workers (HCWs) due to occupational exposure. While previous studies have primarily evaluated HCW immunity using seroprevalence, no study has comprehensively assessed immunity by incorporating other widely used definitions, including documented evidence of immunity, natural immunity by birth cohort, and self-reported immunity.</div></div><div><h3>Methods</h3><div>A systematic review was conducted of HCW immunity surveillance studies published in English in peer-reviewed journals from January 2013 to February 2024. Data were extracted on (1) country, (2) author and year, (3) immunity assessment type, (4) study type, (5) data collection period, (6) immunity coverage results, (7) HCW count, (8) age ranges, (9) job roles, and (10) seroprevalence methodology and threshold values, where applicable.</div></div><div><h3>Results</h3><div>A total of 98 studies were included, with immunity coverage ranging from 57.1 % to 99.2 %. Immunity assessments were based on seroprevalence, documented evidence, natural immunity by birth cohort, and self-reported immunity. Considerable heterogeneity was observed across study populations, immunity assessment methodologies, and situational contexts, including studies conducted during outbreaks. Studies included demonstrated that recall may underestimate immunity, as a high rate of seropositivity was observed among participants who did not remember being vaccinated or having measles.</div></div><div><h3>Conclusion</h3><div>This study highlights a positive trend in HCW immunity coverage compared to previous findings. However, significant methodological variability in assessing measles immunity limits the ability to perform aggregated global analyses. Studies using only one method to assess immunity contribute to the perception of lower-than-expected immunity coverage, as this limited approach may not provide a complete or accurate picture of actual immunity levels. Future research should prioritize the development of standardized tools and methodologies to enable data harmonization and facilitate robust global immunity assessments.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"57 ","pages":"Article 127214"},"PeriodicalIF":4.5,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143937699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measles-mumps-rubella booster and post-COVID-19 immunity: A retrospective cohort study","authors":"Ladislav Štěpánek ,&nbsp;Marie Nakládalová ,&nbsp;Alena Boriková ,&nbsp;Dagmar Horáková ,&nbsp;Lubomír Štěpánek ,&nbsp;Renata Večeřová ,&nbsp;Pavel Sauer","doi":"10.1016/j.vaccine.2025.127232","DOIUrl":"10.1016/j.vaccine.2025.127232","url":null,"abstract":"<div><h3>Background</h3><div>The potential cross-protective effect of measles, mumps, and rubella (MMR) vaccination against coronavirus disease 2019 (COVID-19) is debated. Although immunological studies suggest cross-reactivity between MMR-induced immunity and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), epidemiological evidence remains inconclusive. This study examined the association between an additional MMR dose and both COVID-19 clinical and serological outcomes in an adult cohort with verified pre-pandemic measles immunity.</div></div><div><h3>Methods</h3><div>In 2019, prior to the COVID-19 pandemic, 3027 healthcare workers from a Czech university hospital underwent measles serology testing. Seronegative individuals were offered a single additional MMR dose. Between 2020 and 2021, 261 individuals from the original sample subsequently contracted COVID-19 and underwent post-infection SARS-CoV-2 immunoglobulin G (IgG) serology testing, having remained unvaccinated against COVID-19 until that time.</div></div><div><h3>Results</h3><div>Among 212 women and 49 men (mean age: 42.7 years), 150 were measles-seropositive (without additional vaccination) and 111 were measles-seronegative but received an additional MMR dose. Following COVID-19, 216 participants (82.8 %) exhibited SARS-CoV-2 IgG seropositivity. No significant relationship was observed between measles immunity or MMR vaccine administration and COVID-19 clinical characteristics. However, individuals who received an additional MMR dose were significantly more likely to develop SARS-CoV-2 IgG seropositivity (88.3 % vs. 78.7 %; <em>p</em> = 0.042). Regression analysis confirmed additional MMR vaccination as an independent predictor of post-COVID-19 seropositivity (odds ratio 1.81, 95 % confidence interval 1.17–2.81, <em>p</em> = 0.008), irrespective of the interval between MMR vaccination and COVID-19 symptom onset. No correlation was found between pre-pandemic measles antibody titers and SARS-CoV-2 antibody levels (<em>r</em> = 0.09, <em>p</em> = 0.246).</div></div><div><h3>Conclusion</h3><div>While no protective effect of adult MMR vaccination on COVID-19 clinical outcomes was observed, a significant immunological interaction was identified. These findings align with the concept of trained immunity and warrant further investigation.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"57 ","pages":"Article 127232"},"PeriodicalIF":4.5,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143937703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Herpes simplex virus 1 fusion glycoprotein B H516P prefusion mutation had no effect on vaccine immunogenicity","authors":"Jingping Hu ,&nbsp;Han Cao ,&nbsp;Ning Luan,&nbsp;Xiaolong Zhang,&nbsp;Bingyan Liang,&nbsp;Dandan Gao,&nbsp;Zhentao Lei,&nbsp;Yanwei Bi,&nbsp;Cunbao Liu","doi":"10.1016/j.vaccine.2025.127241","DOIUrl":"10.1016/j.vaccine.2025.127241","url":null,"abstract":"<div><div>Herpes simplex virus (HSV) is a prevalent virus worldwide that is capable of causing a range of diseases, including mucocutaneous lesions in oral and genital regions. More importantly, HSV can cause encephalitis or meningitis under rare circumstances. As a result of the complicated membrane fusion mechanism of HSV, there are still no licensed vaccines at present, although many HSV vaccines are in the clinical trial stage. gD, gH, gL and gB are the main HSV membrane glycoproteins involved in the fusion process. When triggered by receptor binding or exposure to acidic pH, the gB protein undergoes a conformational change, in which hydrophobic residues are inserted into the host membrane. It then folds back on itself to bring the virus and host membranes together. In this study, we designed a sequence to replace histidine 516 in gB with a proline to stabilize the prefusion gB structure. Three different formulations of the vaccine were developed: a subunit vaccine incorporating oligodeoxynucleotides with CpG motifs (CpG ODNs) and QS-21 as adjuvants, a subunit vaccine with an alum adjuvant, and an mRNA vaccine. BALB/c mice were injected intramuscularly with the vaccines to evaluate the immunogenicity of gB and gB H516P and to assess the efficacy of QS-21 and CpG ODNs as adjuvants. The results revealed that the immunogenicity of the gB and gB H516P proteins did not significantly affect humoral and cellular immune responses. However, the combination of QS-21 and CpG ODNs enhanced cellular immune responses compared with the alum adjuvant, but there was no significant difference in neutralizing antibody titers. After being infected with the HSV-1 Mckrae wild-type strain, all the vaccine groups of BALB/c mice were protected from infection, and the mice did not die or experience obvious loss of body weight.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"57 ","pages":"Article 127241"},"PeriodicalIF":4.5,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143931559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can levels of HPV vaccine knowledge mitigate HPV vaccine hesitation among guardians of children aged 9–14 years? A moderated mediation model","authors":"Yan Xiong ,&nbsp;Chengbing Wu ,&nbsp;Yidan Zhang ,&nbsp;Dan Guo ,&nbsp;Jing Wang ,&nbsp;Lijie Du ,&nbsp;Le Yang ,&nbsp;Jingmin Cheng","doi":"10.1016/j.vaccine.2025.127208","DOIUrl":"10.1016/j.vaccine.2025.127208","url":null,"abstract":"<div><h3>Purpose</h3><div>Children aged 9–14 years are the primary target demographic for human papilloma virus (HPV) vaccination, and the hesitancy of guardians in this age group regarding HPV vaccination is likely to significantly impact vaccination rates among children. Understanding the relationship between Levels of HPV Vaccine Knowledge, HPV Vaccine Health Beliefs, and HPV Vaccine Hesitancy is a crucial prerequisite for improving HPV vaccination rates among children aged 9–14.</div></div><div><h3>Method</h3><div>We recruited 5219 guardians of children aged 9–14 years in Shanxi Province, China, using a multistage random sampling method. Participants completed a questionnaire assessing Levels of HPV Vaccine Knowledge, HPV Vaccine Health Beliefs, HPV Vaccine Hesitancy, and demographic characteristics, including the current vaccination status of children aged 9–14.</div></div><div><h3>Results</h3><div>Employing the SPSS macro program PROCESS Model 7, we developed a moderated mediation model. The findings of the study reveal the following: 1) A significant direct effect of HPV vaccine knowledge on HPV vaccine hesitancy was observed; 2) The association between HPV vaccine knowledge and HPV vaccine hesitancy is partially mediated by HPV vaccine health beliefs; 3) The place of residence moderates the initial segment of the mediation effect, with HPV vaccine knowledge exerting a stronger positive predictive effect on health beliefs in rural areas.</div></div><div><h3>Conclusion</h3><div>These results contribute novel insights to the existing literature by elucidating the underlying mechanisms between Levels of HPV Vaccine Knowledge and HPV Vaccine Hesitancy. These findings hold significant implications for enhancing HPV vaccination rates among children aged 9–14.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"57 ","pages":"Article 127208"},"PeriodicalIF":4.5,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143928426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trained immunity-based Adjuvated vaccines (TIbAV) approach: β-glucans as example","authors":"Miriam Angulo ,&nbsp;Abel Ramos-Vega ,&nbsp;Carlos Angulo","doi":"10.1016/j.vaccine.2025.127240","DOIUrl":"10.1016/j.vaccine.2025.127240","url":null,"abstract":"<div><div>The induction of trained immunity (TRIM) has emerged as an approach to fight against diseases. Several β-glucans and vaccines have been identified as trained immunity inductors, allowing heterologous protection for infectious diseases. Curiously, β-glucans from yeast, fungal, and plant species have been evaluated in clinical trials as vaccine adjuvants to combat infectious and non-communicable diseases. However, their adjuvant use for trained immunity-based vaccines (TIbV) remains scarcely studied. In this context, this review brings a scientific panorama of β-glucans and vaccines and offers perspectives on their combination to potentiate trained immunity induction and its benefits. In agreement with TRIM and TIbV concepts, we propose trained immunity-based adjuvanted vaccines (TIbAV) to refer to studies regarding this approach.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"57 ","pages":"Article 127240"},"PeriodicalIF":4.5,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143928424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BactiVac, the Bacterial Vaccines Network","authors":"Calman A. MacLennan ,&nbsp;Adam F. Cunningham ,&nbsp;Johanna E. Dean ,&nbsp;Susan Pope ,&nbsp;Evelina Balandyte-Shergill ,&nbsp;Jamie Pillaye ,&nbsp;Brian M. Greenwood ,&nbsp;Richard A. Adegbola ,&nbsp;on behalf of the BactiVac Network Group of Authors","doi":"10.1016/j.vaccine.2025.127210","DOIUrl":"10.1016/j.vaccine.2025.127210","url":null,"abstract":"<div><div>Bacterial vaccines save lives and constitute a major tool to address the challenge of anti-microbial resistance, though, despite their success, there is a relative paucity of such vaccines. Historically there has not been a network that focuses on bacterial vaccines, to promote sharing of approaches and best practices, and provide advocacy. BactiVac, the Bacterial Vaccines Network, was established in August 2017 to address this gap. Its mission is to advance vaccine development against global bacterial infections in humans and animals, to reduce disease, death, and antimicrobial resistance, and thereby enhance economic development. BactiVac brings together academia, industry, policymakers and funders from high-income countries (HICs) and low- and middle-income countries (LMICs), in a network of 2060 members from 92 countries, including 51 % from LMICs and 15 % from industry. BactiVac supports vaccine development through Catalyst Project Awards and Catalyst Training Awards. This funding targets bottlenecks and capacity-building in vaccinology, particularly among LMIC early-career researchers. Annual Network Meetings facilitate exchange of information and ideas, and new collaborations. We provide advocacy for bacterial vaccines nationally and internationally and, by partnering with aligned networks, function as a network within a network of networks. Therefore, through providing financial support and facilitating collaboration, BactiVac supports and enhances the bacterial vaccinology community to help reduce the devastating burden of disease caused by bacterial infections.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"57 ","pages":"Article 127210"},"PeriodicalIF":4.5,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143928427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}